Mineralys Therapeutics, Inc. (MLYS)
15.33
+0.09
(+0.59%)
USD |
NASDAQ |
Nov 06, 16:00
15.34
+0.01
(+0.07%)
After-Hours: 20:00
Mineralys Therapeutics Total Liabilities (Quarterly) : 126.35M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 126.35M |
| June 30, 2026 | 116.94M |
| March 31, 2026 | 14.72M |
| December 31, 2025 | 15.11M |
| September 30, 2025 | 23.52M |
| June 30, 2025 | 22.17M |
| March 31, 2025 | 13.39M |
| December 31, 2024 | 14.65M |
| September 30, 2024 | 31.32M |
| June 30, 2024 | 28.40M |
| Date | Value |
|---|---|
| March 31, 2024 | 19.20M |
| December 31, 2023 | 10.48M |
| September 30, 2023 | 13.54M |
| June 30, 2023 | 6.207M |
| March 31, 2023 | 10.56M |
| December 31, 2022 | 8.067M |
| September 30, 2022 | 7.22M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 5.054M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.637B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 630.12M |
| Shareholders Equity (Quarterly) | 503.78M |
| Debt to Equity Ratio | 0.1951 |
| Current Ratio | 11.83 |
| Net Debt Paydown Yield | -0.88% |